TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05762302: The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER"

Sponsor: MeMed Diagnostics Ltd. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 1316 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT05762302 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05762302 Rescue Dossier →